C4 Therapeutics, Inc.

CCCC · Nasdaq · United States

Share price · CCCC

$2.48-1.70 (-40.79%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.8M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CCCC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Oct 2026+10.9%
  2. 2 Oct 2026-6.1%
  3. 30 Sep 2026+6.4%
  4. 29 May 2026+19.4%
  5. 13 May 2026+16.1%
  6. 10 Mar 2026-13.1%
  7. 9 Mar 2026+18.1%
  8. 2 Mar 2026+17.4%
  9. 25 Feb 2026+15.9%
  10. 19 Feb 2026+11.0%

Share of unusual movement by asset

For each asset, the share of CCCC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Cemsidomide
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—80%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Cereblon E3 ubiquitin-ligaseSmall molecule
Multiple Myeloma
Phase 1
EGFR L858R (including T790M/C797S resistant mutants)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
March 2030 (1)
CemsidomidePhase 2Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Est. primary completion 2030-03 · NCT07284758 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$8.5M$25M$36M+ $173M short-term inv.$22M-$26M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$6.6M$24M$82M+ $222M short-term inv.$24M-$1.6M operating cash flowreport ↗
2026-Q1$6.2M$25M$65M+ $207M short-term inv.$25M-$30M operating cash flowreport ↗
2025-Q3$11M$26M$62M+ $141M short-term inv.$32M-$31M operating cash flowreport ↗
2025-Q2$6.5M$26M$82M+ $145M short-term inv.$26M-$12M operating cash flowreport ↗
2025-Q1$7.2M$27M$55M+ $183M short-term inv.$26M-$33M operating cash flowreport ↗
2024-Q3$15M$32M$63M+ $225M short-term inv.$25M-$24M operating cash flowreport ↗
2024-Q2$12M$24M$77M+ $223M short-term inv.$18M-$5.0M operating cash flowreport ↗
2024-Q1$3.0M$23M$93M+ $210M short-term inv.$28M-$18M operating cash flowreport ↗
2023-Q3$11M$28M$64M+ $185M short-term inv.$27M-$31M operating cash flowreport ↗
2023-Q2$2.7M$30M$48M+ $242M short-term inv.$36M-$19M operating cash flowreport ↗
2023-Q1$3.8M$29M$53M+ $256M short-term inv.$35M-$33M operating cash flowreport ↗
2022-Q3$6.8M$30M$53M+ $264M short-term inv.$32M-$28M operating cash flowreport ↗
2022-Q2$14M$31M$61M+ $250M short-term inv.$27M-$22M operating cash flowreport ↗
2022-Q1$7.7M$26M$49M+ $245M short-term inv.$32M-$27M operating cash flowreport ↗
2021-Q3$8.5M$24M$164M+ $239M short-term inv.$25M-$18M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$36M$104M$78M+ $223M short-term inv.$26M-$99M operating cash flowreport ↗

C4 Therapeutics, Inc. reported revenue of $35.95M, up 1.0% YoY, R&D spend of $104.24M, down 5.8% YoY, cash and equivalents of $78.05M, and a net loss of $104.99M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$36M$111M$59M+ $212M short-term inv.$26M-$65M operating cash flowreport ↗
2023-FY$21M$118M$130M+ $155M short-term inv.$33M-$107M operating cash flowreport ↗
2022-FY$31M$118M$33M+ $307M short-term inv.$32M-$106M operating cash flowreport ↗
2021-FY$46M$95M$79M+ $233M short-term inv.$21M-$87M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($145K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12Adams Kendra · Chief Financial OfficerOpen-market sale45,173$2.71$122KForm 4
2026-10-01GROGAN DONNA ROY · directorAward / grant4,618$3.14$15KForm 4
2026-10-01Anderson Kenneth Carl · directorAward / grant3,662$3.14$11KForm 4
2026-09-18Adams Kendra · Chief Financial OfficerOption exercise6,250——Form 4
2026-09-18Adams Kendra · Chief Financial OfficerTax withholding2,775$3.39$9KForm 4
2026-07-10REYNO LEONARD · Chief Medical OfficerOption exercise15,325——Form 4
2026-07-10REYNO LEONARD · Chief Medical OfficerTax withholding7,397$4.06$30KForm 4
2026-07-01GROGAN DONNA ROY · directorAward / grant3,341$4.34$14KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 123 reporting institutions held 84.9M shares ($216.9M, 76.8% of shares outstanding).

#InstitutionSharesValue
1MORGAN STANLEY9,072,400$23.9M
2RA CAPITAL MANAGEMENT, L.P.8,000,000$21.0M
3Bain Capital Life Sciences Investors, LLC7,171,910$18.9M
4Lynx1 Capital Management LP6,998,902$18.4M
5VANGUARD CAPITAL MANAGEMENT LLC3,861,852$10.2M
6Soleus Capital Management, L.P.3,803,942$10.0M
7TWO SIGMA INVESTMENTS, LP3,035,634$8.0M
8WASATCH ADVISORS LP2,961,761$7.8M
9JPMORGAN CHASE & CO3,223,054$7.6M
10CITADEL ADVISORS LLC2,511,015$6.6M
11RENAISSANCE TECHNOLOGIES LLC2,461,815$6.5M
12GOLDMAN SACHS GROUP INC2,387,378$6.3M
13BANK OF AMERICA CORP /DE/2,359,241$6.2M
14Squadron Capital Management LLC2,250,000$5.9M
15BlackRock, Inc.2,048,526$5.4M